From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Stopping PCP Prophylaxis Appears Safe for Some HIV+ Patients

Once the most common opportunistic infection in AIDS, Pneumocystis carinii pneumonia (PCP) is now a rarity among HIV-infected patients taking combination antiretroviral therapy, and many clinicians suspect that these patients no longer need lifelong PCP prophylaxis with trimethoprim-sulfamethoxazole or other drugs. Two European studies address this issue.

One retrospectively examined data from more than 7,000 HIV-infected patients enrolled in an ongoing cohort study. About 3,000 were receiving PCP prophylaxis at the time they began combination therapy that included a protease inhibitor. Over two years, 319 patients stopped primary prophylaxis, and 59 stopped secondary prophylaxis, a median of 10 months after protease-containing treatment was begun. No cases of PCP were seen in either group after 247 person-years of follow up.

The second study prospectively followed 262 patients who had stopped primary PCP prophylaxis after at least three months of combination antiretroviral therapy. Median CD4 count at the time prophylaxis was stopped was 325 cells/mm3, and median viral load was 100 copies/ml. After almost a year of follow-up, no cases of PCP developed among these patients.

Comment: These results suggest that the risk for PCP becomes small enough with successful antiretroviral treatment that most patients may safely stop prophylaxis. But both groups of authors caution that prophylaxis should be continued for several months after CD4 cell counts rebound -- one editorialist suggests at least six months -- and the question of whether prophylaxis should be reinstituted if CD4 counts drop again remains to be answered.

— A Zuger

Published in Journal Watch General Medicine May 7, 1999

Citation(s):

Weverling GJ et al. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 1999 Apr 17 353 1293-1298.

Feinberg J. Withdrawal of prophylaxis against Pneumocystis carinii pneumonia. Lancet 1999 Apr 17 353 1287-1287.

Furrer H et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infected adults treated with combination antiretroviral therapy. N Engl J Med 1999 Apr 29 340 1301-1306.

Masur H and Kaplan J. Does Pneumocystis carinii prophylaxis still need to be lifelong?. N Engl J Med 1999 Apr 29 340 1356-1357.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 1999. Massachusetts Medical Society. All rights reserved.